Statistics Collaborative - Design and analysis for biomedical research

PublicationsPublications

Zi-Fan Yu

  • Wittes J, Yu Z. Design and Analysis of Randomized Clinical Trials. In: Hinkelmann K, ed. Design and Analysis of Experiments. New York: John Wiley, 165-211, 2012.
  • Harmatz P, Yu ZF, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Swiedler SJ, Hardy K, Berger KI, Decker C. Enzyme replacement therapy for mucopolysaccharidosis VI: Evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis 2010; 33:51-60.
  • Decker C, Yu Z, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda CS, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Swiedler SJ, Conrad S, Harmatz P, for the MPS VI Study Group. Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Ped Rehab Med 2010; 3:89-100.
  • Yu ZF, Catalano PJ. A simulation study of quantitative risk assessment for bivariate continuous outcomes. Risk Anal 2008; 28:1415-1430.

  • Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Yu ZF, Swiedler SJ, Decker C. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 2008; 94:469-475.

  • Bavaria JE, Appoo JJ, Makaroun MS, Verter J, Yu Z, Mitchell RS. Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: a multicenter comparative trial. J Thorac Cardiovasc Surg 2007; 133:369-377.

  • Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda M, Wraith J, Beck M, Arash L, Scarpa M, Yu Z, Wittes J, Berger K, Newman M, Lowe A, Kakkis E, Swiedler S, MPS VI Phase 3 Study Group. Enzyme replacement therapy for Mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsufatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006; 148:533-539.

  • Yu Z, Catalano P, Quantitative risk assessment for multivariate continuous outcomes with application to neurotoxicology: the bivariate case. Biometrics 2005; 61:757‑766.

  • Harmatz P, Ketteridege D, Giugliani R, Guffon N, Teles EL, Sa Miranda MC, Oates S, Yu Z, Sweidler SJ, Hopwood JJ. Direct comparison of measures of endurance, mobility, and joint function during enzyme replacement therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): results after 48 weeks in a Phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4‑sulfatase. Pediatrics 2005; 115:681-689.

  • Radjev L, Yu Z, Wadler S, Weller E, Kahn S, Tormey D, Skeel R, Wiernick P. N Methylformamide in advanced squamous cancer of the uterine cervix: an Eastern Cooperative Oncology Group phase II trial. Invest New Drugs 2001; 19:233-237.